Literature DB >> 2371565

Regulation of proteolysis at the neutrophil-substrate interface by secretory leukoprotease inhibitor.

W G Rice1, S J Weiss.   

Abstract

Human neutrophils can initiate the rapid degradation of extracellular matrix macromolecules by localizing the destructive process to sites of cell-substrate contact. Although plasma and its filtrates contain multiple proteinase inhibitors, these inhibitors did not prevent neutrophils from attacking either underlying fibronectin or elastin. However, subjacent substrates could be protected from neutrophils by recombinant secretory leukoprotease inhibitor, a structurally unique serine proteinase inhibitor whose natural counterpart is normally confined to human mucous secretions. The identification of this extravascular proteinase inhibitor as a potent regulator of subjacent proteolysis could lead to the development of a new class of anti-inflammatory therapeutics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2371565     DOI: 10.1126/science.2371565

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  36 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Interstitial collagenase (matrix metalloproteinase-1) expresses serpinase activity.

Authors:  P E Desrochers; J J Jeffrey; S J Weiss
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 3.  A massage for the journey: keeping leukocytes soft and silent.

Authors:  U H von Andrian
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

4.  Neutrophil serine proteases exert proteolytic activity on endothelial cells.

Authors:  Uwe Jerke; Daniel Perez Hernandez; Patrick Beaudette; Brice Korkmaz; Gunnar Dittmar; Ralph Kettritz
Journal:  Kidney Int       Date:  2015-06-10       Impact factor: 10.612

5.  Plasma levels of elastase-specific fibrinopeptides correlate with proteinase inhibitor phenotype. Evidence for increased elastase activity in subjects with homozygous and heterozygous deficiency of alpha 1-proteinase inhibitor.

Authors:  J I Weitz; E K Silverman; B Thong; E J Campbell
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

6.  β2 integrin-mediated cell-cell contact transfers active myeloperoxidase from neutrophils to endothelial cells.

Authors:  Uwe Jerke; Susanne Rolle; Bettina Purfürst; Friedrich C Luft; William M Nauseef; Ralph Kettritz
Journal:  J Biol Chem       Date:  2013-03-26       Impact factor: 5.157

7.  Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor.

Authors:  N G McElvaney; H Nakamura; P Birrer; C A Hébert; W L Wong; M Alphonso; J B Baker; M A Catalano; R G Crystal
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

8.  Neutrophil-mediated proteolysis. Differential roles for cathepsin G and elastase.

Authors:  P Kubes; R Smith; M D Grisham; D N Granger
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

9.  Expression of serine proteinases and metalloproteinases in organ-cultured human skin. Altered levels in the presence of retinoic acid and possible relationship to retinoid-induced loss of epidermal cohesion.

Authors:  J Varani; B Burmeister; R G Sitrin; S B Shollenberger; D R Inman; S E Fligiel; D F Gibbs; K Johnson
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

10.  Inhibition by recombinant SLPI and half-SLPI (Asn55-Ala107) of elastase and cathepsin G activities: consequence for neutrophil-platelet cooperation.

Authors:  P Renesto; V Balloy; T Kamimura; K Masuda; A Imaizumi; M Chignard
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.